Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBT-1 in subjects undergoing cardiac surgery
NCT06021457Phase 3Completed
- Sponsor
- Renibus Therapeutics
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial comparing RBT-1 with Placebo (2 arms). Primary endpoint: Hierarchical composite of death, AKI requiring dialysis, 30-day cardiopulmonary readmission, and ICU days. Started Oct 2023; status: completed.
02
Drugs
stannic protoporfin + iron sucrose
Beyond the preview
Go deeper on NCT06021457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06021457.